by Paul Krzyzanowski | May 16, 2012
Commercialization plenary summary: part 4 of 4 The last speaker of the commercialization plenary at the Till and McCulloch Meetings earlier this month was Dr. Stephen Minger from GE Healthcare, who shared GE’s perspective regarding the therapeutic and research...
by Stem Cell Network | May 11, 2012
By all accounts, the 35 entries in this year’s Cells I See Art Contest & Gallery Showing were among the best we’ve ever had. Certainly, there were more than we’d ever seen before (view them all here) — so many, in fact, that we had...
by David Kent | May 8, 2012
The final day of the 2012 Till and McCulloch Meetings was packed with great science, but a common theme definitely emerged – technological advances are changing the way we think about and perform scientific research. Keynote speaker Helen Blau issued a warning...
by Paul Krzyzanowski | May 4, 2012
Commercialization plenary summary: part 3 of 4 On day two (May 1) of the Till and McCulloch Meetings, Dr. Emily Culme-Seymour from the London Regenerative Medicine Network introduced work that leverages previous clinical trial information to support future cell...
by David Kent | May 2, 2012
Anticipatory ethics and the problem of expectations One of my favorite things about Canadian Stem Cell Network meetings (now renamed the Till and McCulloch Meetings) is the integration into the main programming of Ethical, Legal, and Social Issues (ELSI). It...
Comments